Craft

Sunmax Biotechnology

Stock Price

NT$266.5

2024-10-29

Market Capitalization

NT$14.5 B

2024-10-29

Revenue

NT$2 B

FY, 2025

Sunmax Biotechnology Summary

Company Summary

Overview
Sunmax Biotechnology is a company that manufactures and markets collagen-based medical devices. It offers dermal filler, dental, orthopedic, skincare, laboratory, and other product categories.
Type
Public
Status
Active
Founded
2001
Website
https://www.sunmaxbiotech.com/
Cybersecurity rating
Sectors

Table of Contents

Sunmax Biotechnology Financials

Summary Financials

Revenue (Q1, 2026)
NT$564.8M
Gross profit (Q1, 2026)
NT$480.7M
Net income (Q1, 2026)
NT$221.6M
Cash (Q1, 2026)
NT$1.1B
EBIT (Q1, 2026)
NT$297.0M
Enterprise value
$13.5B

Footer menu